There are 2789 resources available
1105P - Predictive factors of adverse events onset in GEPNET patients treated with PRRT
Presenter: Federica Scalorbi
Session: ePoster Display
1106P - Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms
Presenter: Timothy Price
Session: ePoster Display
1033TiP - A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
Presenter: Kyriakos Papadopoulos
Session: ePoster Display
1034TiP - ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma
Presenter: Richard Carvajal
Session: ePoster Display
1110P - COVID-19 pandemic impact on healthcare professionals treating patients with neuroendocrine tumors (NET): An international NET CONNECT survey
Presenter: Jorge Hernando
Session: ePoster Display
1042P - Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
Presenter: Ines Pires da Silva
Session: ePoster Display
1113P - Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America
Presenter: Teodora Kolarova
Session: ePoster Display
1114P - Comparative study of combined large cell neuroendocrine carcinoma and combined small cell carcinoma in resected high-grade neuroendocrine tumors of the lung
Presenter: Yanan Wang
Session: ePoster Display
1115P - Beyond classic hereditary neuroendocrine tumors (NET) syndromes
Presenter: Carmen Castillo Manzano
Session: ePoster Display
1116P - Well-differentiated neuroendocrine tumors of the kidney: Clinical characterics and treatment outcomes of a very rare disease
Presenter: Leonidas Apostolidis
Session: ePoster Display